Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Willem Bram De Rijk"'
Autor:
Isabel Cuella-Martin, Jean Claude Semuto Ngabonziza, Gabriela Torrea, Conor Joseph Meehan, Wim Mulders, Bertin Ushizimpumu, Louise De Weerdt, Jelle Keysers, Willem Bram De Rijk, Tom Decroo, Bouke C De Jong, Leen Rigouts
Publikováno v:
International Journal of Mycobacteriology, Vol 12, Iss 3, Pp 274-281 (2023)
Background: The World Health Organization-endorsed phenotypic and genotypic drug-susceptibility testing (gDST/pDST) assays for the detection of rifampicin-resistant (RR) tuberculosis (TB), may miss some clinically relevant rpoB mutants, including bor
Externí odkaz:
https://doaj.org/article/7a88442c84f742f5967729b57118eea6
Autor:
Jean Claude Semuto Ngabonziza, MSc, Tom Decroo, PhD, Patrick Migambi, MSc, Yves Mucyo Habimana, MD, Armand Van Deun, PhD, Conor J Meehan, PhD, Gabriela Torrea, PhD, Faridath Massou, PharmD, Willem Bram de Rijk, BS, Bertin Ushizimpumu, BS, Esdras Belamo Niyigena, BS, Emil Ivan, PhD, Jules Mugabo Semahore, MD, Jean Baptiste Mazarati, PhD, Corinne Simone Merle, PhD, Philip Supply, PhD, Dissou Affolabi, ProfPhD, Leen Rigouts, PhD, Bouke Catherine de Jong, ProfPhD
Publikováno v:
The Lancet Microbe, Vol 1, Iss 2, Pp e74-e83 (2020)
Summary: Background: The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert. Methods:
Externí odkaz:
https://doaj.org/article/77bfaae837f3401fad6757b6a7eea198
Autor:
Jean Claude Semuto Ngabonziza, Awa Ba Diallo, Elisa Tagliani, Bassirou Diarra, Abalo Essosimna Kadanga, Antieme Combo George Togo, Aliou Thiam, Willem Bram de Rijk, Riccardo Alagna, Sabine Houeto, Fatoumata Ba, Anoumou Yaotsè Dagnra, Emil Ivan, Dissou Affolabi, Valérie Schwoebel, Arnaud Trebucq, Bouke Catherine de Jong, Leen Rigouts, Géraldine Daneau, “Union short MDR-TB regimen study group”
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0187211 (2017)
Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are contradictory a
Externí odkaz:
https://doaj.org/article/8ba3bf05f6a04070aad504423497ccab
Autor:
Miriam Eddyani, Caroline Lavender, Willem Bram de Rijk, Pieter Bomans, Janet Fyfe, Bouke de Jong, Françoise Portaels
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e89407 (2014)
BACKGROUND:Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU), a necrotizing disease of the skin, soft tissue and bone. PCR is increasingly used in the diagnosis of BU and in research on the mode of transmission and environmental rese
Externí odkaz:
https://doaj.org/article/8cdf25f7bc9549e4a03ad791b33ed004
Autor:
Faridath Massou, Patrick Migambi, Armand Van Deun, Dissou Affolabi, Corinne S Merle, Bertin Ushizimpumu, Esdras Belamo Niyigena, Jean Baptiste Mazarati, Leen Rigouts, Bouke C. de Jong, Conor J. Meehan, Emil Ivan, Philip Supply, Jules Mugabo Semahore, Willem Bram de Rijk, Tom Decroo, Gabriela Torrea, Yves Mucyo Habimana, Jean Claude Semuto Ngabonziza
Publikováno v:
Lancet microbe
The Lancet Microbe
The Lancet Microbe, Elsevier, 2020, 1 (2), pp.e74-e83. ⟨10.1016/S2666-5247(20)30007-0⟩
The Lancet Microbe, 2020, 1 (2), pp.e74-e83. ⟨10.1016/S2666-5247(20)30007-0⟩
The Lancet Microbe, Vol 1, Iss 2, Pp e74-e83 (2020)
The Lancet Microbe
The Lancet Microbe, Elsevier, 2020, 1 (2), pp.e74-e83. ⟨10.1016/S2666-5247(20)30007-0⟩
The Lancet Microbe, 2020, 1 (2), pp.e74-e83. ⟨10.1016/S2666-5247(20)30007-0⟩
The Lancet Microbe, Vol 1, Iss 2, Pp e74-e83 (2020)
Summary Background The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert. Methods We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac9c3937ab1c223d8876192a9c61ba9
https://pubmed.ncbi.nlm.nih.gov/35544156
https://pubmed.ncbi.nlm.nih.gov/35544156
Autor:
Willem Bram de Rijk, Sabira Tahseen, Leen Rigouts, M A Hossain, Armand Van Deun, Tom Decroo, Bouke C. de Jong, M Gumusboga, K. J. M. Aung
Publikováno v:
European Respiratory Journal. 58:2100783
Despite their name, borderline rpoB mutations are correlated with unfavourable outcomes when rifampicin-throughout treatment is used. They may become the drivers of rifampicin-resistant tuberculosis. Second-line treatment is recommended. Footnotes Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ee49584cb45433080156c910eb402d7
https://doi.org/10.1183/13993003.00783-2021
https://doi.org/10.1183/13993003.00783-2021
Autor:
Antieme Combo George Togo, Abalo Essosimna Kadanga, Aliou Thiam, Bouke C. de Jong, Leen Rigouts, Elisa Tagliani, Fatoumata Ba, Awa Ba Diallo, Riccardo Alagna, Géraldine Daneau, V Schwoebel, Willem Bram de Rijk, Dissou Affolabi, Sabine Houeto, Emil Ivan, Anoumou Yaotsè Dagnra, Jean Claude Semuto Ngabonziza, Bassirou Diarra, Arnaud Trébucq
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 10, p e0187211 (2017)
PLoS ONE, Vol 12, Iss 10, p e0187211 (2017)
Background Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1875c433699cee0f82cbc85c668276a4
https://hdl.handle.net/10067/1474250151162165141
https://hdl.handle.net/10067/1474250151162165141
Autor:
Françoise Portaels, Janet A. M. Fyfe, Caroline J. Lavender, Willem Bram de Rijk, Bouke C. de Jong, Pieter Bomans, Miriam Eddyani
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e89407 (2014)
PLoS ONE; Vol 9
PLoS ONE
PLoS ONE; Vol 9
PLoS ONE
Background Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU), a necrotizing disease of the skin, soft tissue and bone. PCR is increasingly used in the diagnosis of BU and in research on the mode of transmission and environmental rese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75d700873fd216929296a3237b3b55a4
http://europepmc.org/articles/PMC3931755?pdf=render
http://europepmc.org/articles/PMC3931755?pdf=render
Autor:
Valentin Bola, Armand Van Deun, Gabriela Torrea, K. J. M. Aung, Aysel Gumusboga, Leen Rigouts, Rossin Lebeke, Bouke C. de Jong, M A Hossain, Willem Bram de Rijk
The rapid diagnosis of rifampin resistance is hampered by a reported insufficient specificity of molecular techniques for detection of rpoB mutations. Our objective for this study was to document the prevalence and prognostic value of rpoB mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d1ca12f40a893ecb9c88da8fba842e2
https://europepmc.org/articles/PMC3719626/
https://europepmc.org/articles/PMC3719626/
Autor:
Leen Rigouts, M Gumusboga, Bouke C. de Jong, Cécile Uwizeye, Armand Van Deun, Elie Nduwamahoro, Willem Bram de Rijk
Publikováno v:
Journal of clinical microbiology
WHO-endorsed phenotypic drug susceptibility testing (DST) methods for Mycobacterium tuberculosis are assumed to be the gold standard for identifying rifampin (RMP) resistance. However, previous results indicated that low-level, yet probably clinicall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::283a3cd13a936a2f9c4c18cf76b89328
https://europepmc.org/articles/PMC3719602/
https://europepmc.org/articles/PMC3719602/